Carlos Perez-Sanchez
Overview
Explore the profile of Carlos Perez-Sanchez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Arias-de la Rosa I, Escudero-Contreras A, Ruiz-Ponce M, Cuesta-Lopez L, Roman-Rodriguez C, Perez-Sanchez C, et al.
iScience
. 2022 Sep;
25(9):104893.
PMID: 36046189
We aimed to evaluate the association between adipose tissue (AT) dysfunction, autoimmunity, and disease activity in rheumatoid arthritis (RA). A cross-sectional study including 150 RA patients and 50 healthy donors...
12.
Perez-Sanchez C, Barbera Betancourt A, Lyons P, Zhang Z, Suo C, Lee J, et al.
J Exp Med
. 2022 Apr;
219(5).
PMID: 35363256
MicroRNAs are critical regulators of gene expression controlling cellular processes including inflammation. We explored their role in the pathogenesis of inflammatory bowel disease (IBD) and identified reduced expression of miR-374a-5p...
13.
Arias de la Rosa I, Lopez-Montilla M, Roman-Rodriguez C, Perez-Sanchez C, Gomez-Garcia I, Lopez-Medina C, et al.
J Intern Med
. 2022 Mar;
291(5):676-693.
PMID: 35233860
Objectives: (1) To evaluate clinical and molecular cardiovascular disease (CVD) signs and their relationship with psoriatic arthritis (PsA) features and (2) to identify a clinical patient profile susceptible to benefit...
14.
Arias de la Rosa I, Escudero-Contreras A, Ruiz-Ponce M, Roman-Rodriguez C, Perez-Sanchez C, Del Carmen Abalos-Aguilera M, et al.
Front Immunol
. 2021 Nov;
12:744022.
PMID: 34721412
Disease severity, progression and response to therapy might be worse in obese rheumatoid arthritis (RA) patients, but paradoxically, obesity also might protect from radiographic joint damage. Thus, the intricate relationship...
15.
Ibanez-Costa A, Perez-Sanchez C, Patino-Trives A, Luque-Tevar M, Font P, Arias de la Rosa I, et al.
Ann Rheum Dis
. 2021 Oct;
81(1):56-67.
PMID: 34625402
Objectives: To characterise splicing machinery (SM) alterations in leucocytes of patients with rheumatoid arthritis (RA), and to assess its influence on their clinical profile and therapeutic response. Methods: Leucocyte subtypes...
16.
Patino-Trives A, Perez-Sanchez C, Perez-Sanchez L, Luque-Tevar M, Abalos-Aguilera M, Alcaide-Ruggiero L, et al.
Arterioscler Thromb Vasc Biol
. 2021 Jul;
41(9):2417-2430.
PMID: 34320837
Objective: Systemic lupus erythematosus (SLE) is associated to boosted atherosclerosis development and a higher cardiovascular disease risk. This study aimed to delineate the role of anti-double stranded DNA (anti-dsDNA) antibodies...
17.
Ruiz-Limon P, Ladehesa-Pineda M, Lopez-Medina C, Lopez-Pedrera C, Abalos-Aguilera M, Barbarroja N, et al.
Diagnostics (Basel)
. 2021 Jul;
11(6).
PMID: 34199950
Endothelial dysfunction (ED) is well known as a process that can lead to atherosclerosis and is frequently presented in radiographic axial spondyloarthritis (r-axSpA) patients. Here, we investigated cellular and molecular...
18.
Lopez-Pedrera C, Villalba J, Patino-Trives A, Luque-Tevar M, Barbarroja N, Aguirre M, et al.
Antioxidants (Basel)
. 2021 Apr;
10(4).
PMID: 33924642
Coenzyme Q (CoQ) is a mitochondrial electron carrier and a powerful lipophilic antioxidant located in membranes and plasma lipoproteins. CoQ is endogenously synthesized and obtained from the diet, which has...
19.
Luque-Tevar M, Perez-Sanchez C, Patino-Trives A, Barbarroja N, Arias de la Rosa I, Abalos-Aguilera M, et al.
Front Immunol
. 2021 Apr;
12:631662.
PMID: 33833756
This prospective multicenter study developed an integrative clinical and molecular longitudinal study in Rheumatoid Arthritis (RA) patients to explore changes in serologic parameters following anti-TNF therapy (TNF inhibitors, TNFi) and...
20.
Arias de la Rosa I, Font P, Escudero-Contreras A, Lopez-Montilla M, Perez-Sanchez C, Abalos-Aguilera M, et al.
Ther Adv Chronic Dis
. 2021 Apr;
11:2040622320965067.
PMID: 33796240
Objective: To analyze the relationship between complement component 3 (C3) and the prevalence of cardiometabolic risk factors and disease activity in the rheumatic diseases having the highest rates of cardiovascular...